Ask AI
Atopic Dermatitis Utilizing Biologic Therapies

CE / CME

Advancing Atopic Dermatitis Care: Current Evidence on Biologic Therapies for Moderate to Severe Disease

Physician Assistants/Physician Associates: 0.25 AAPA Category 1 CME credit

Nurse Practitioners/Nurses: 0.25 Nursing contact hour

Physicians: maximum of 0.25 AMA PRA Category 1 Credit

Released: July 10, 2025

Expiration: July 09, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

According to clinical trial evidence, how does lebrikizumab differ from tralokinumab in targeting IL-13 for the treatment of moderate to severe AD?